Skip to content
Screener

Sutro Biopharma STRO Total Revenue

Total Revenue at other companies

Pfizer logo
PfizerPFE
$15.03B+2.6%
Gilead Sciences logo
Gilead SciencesGILD
$7.8B+10.2%
Regenxbio logo
RegenxbioRGNX
$108.02M+406%
Xencor logo
XencorXNCR
$51.22M+17.5%
Schrodinger logo
SchrodingerSDGR
$58.89M+7.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$25.56M-8.0%

Segments

By product

See full
Materials Supply$4.45M-20.9%
Ongoing Performance Related To Unsatisfied Performance Obligations$4.18M-91.7%
Financing Component On Unearned Revenue$516K-38.0%
Research And Development Services$495K-18.7%

Other financials

Income statement

See full
Operating income-$29.9M-794%
Net income-$38.5M-235%
EPS (diluted)-$2.33-72.6%

Balance sheet

See full
Cash & equivalents$54.3M-15.1%
Total debt$10.8M-45.0%
Total equity-$103.3M-222%
Total assets$194.5M-25.9%

Cash flow

See full
Operating cash flow-$38.3M+14.4%
CapEx$256.0K—
Free cash flow-$38.5M+13.8%

Valuation

See full
Market cap$264.8M+246%
Enterprise value$221.25M+684%
P/S5.8×+5.1×

Profitability

See full
Operating margin-319.6%+540pp
Net margin-395.2%+18,070pp
FCF margin-318.2%+159pp

Returns & leverage

See full
Return on equity-234.2%—
Debt / equity0.5×+0.3×
Current ratio3.3×+0.2×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Sutro Biopharma’s 10-Q, filed August 12, 2026.

Filed
Aug 12, 2026, 7:30 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-345748
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Revenue$9,839$63,745$24,362$81,144
Operating expenses
Research and development31,69538,32568,24889,922
General and administrative7,83110,34315,41523,616
Restructuring and related costs20118,42224339,465
Total operating expenses39,72767,09083,906153,003
Loss from operations(29,888)(3,345)(59,544)(71,859)
Interest income1,7232,5193,3585,708

Item 1. Financial Statements.

FAQ

What is Sutro Biopharma's total revenue?
Sutro Biopharma (STRO) reported total revenue of $9.84M in Q2 2026.
How has Sutro Biopharma's total revenue changed year-over-year?
Sutro Biopharma's total revenue decreased by 84.6% year-over-year, from $63.75M to $9.84M.
What is the long-term trend for Sutro Biopharma's total revenue?
Over 4 years (2021 to 2025), Sutro Biopharma's total revenue has grown at a 13.4% compound annual growth rate (CAGR), from $61.88M to $102.48M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Sutro Biopharma's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude